Dr. John Iafrate is the director of the Center for Integrated Diagnostics, a clinical laboratory for molecular diagnostics at the MGH. He oversees the Translational Research Laboratory (TRL), a shared effort of the Pathology Department and Mass General Cancer Center. The TRL provides rapid personalized genomic testing to help inform cancer treatment decisions for patients. Dr. Iafrate received his MD and PhD from the State University of New York at Stony Brook in 2000, and was trained in anatomic and molecular genetic pathology at the BWH. He joined the MGH staff in 2005. His post-doctoral work involved the discovery and description of a novel source of human genetic diversity, CNV. He established a cancer diagnostics lab focusing on genetic fingerprints that help guide novel, targeted therapies. His laboratory launched SNaPshot several years ago, an assay that tests over 100 of the most common mutations in tumors. His research is focused on lung and brain tumors, and he has been closely involved in the clinical development of crizotinib and companion diagnostics in ALK-positive and ROS1-positive lung cancers.